Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
159.5 EUR | +0.34% | -0.68% | +14.61% |
07-01 | Merus Names New Chief Medical Officer | MT |
07-01 | AbbVie: new CEO takes up post | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 29.71 and 23.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.61% | 303B | - | ||
+56.86% | 815B | C+ | ||
+43.90% | 641B | B | ||
-6.57% | 352B | C+ | ||
+17.32% | 314B | B- | ||
+16.08% | 242B | B+ | ||
+2.29% | 224B | A+ | ||
+13.96% | 218B | B- | ||
+7.98% | 168B | C+ | ||
-1.98% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- 4AB Stock
- Ratings AbbVie Inc.